These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 20462723)
1. AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Oteo J; Cercenado E; Cuevas O; Bautista V; Delgado-Iribarren A; Orden B; Pérez-Vázquez M; García-Cobos S; Campos J Diagn Microbiol Infect Dis; 2010 Jul; 67(3):270-6. PubMed ID: 20462723 [TBL] [Abstract][Full Text] [Related]
2. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Naseer U; Haldorsen B; Simonsen GS; Sundsfjord A Clin Microbiol Infect; 2010 Feb; 16(2):171-8. PubMed ID: 19548922 [TBL] [Abstract][Full Text] [Related]
3. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. Blanco M; Alonso MP; Nicolas-Chanoine MH; Dahbi G; Mora A; Blanco JE; López C; Cortés P; Llagostera M; Leflon-Guibout V; Puentes B; Mamani R; Herrera A; Coira MA; García-Garrote F; Pita JM; Blanco J J Antimicrob Chemother; 2009 Jun; 63(6):1135-41. PubMed ID: 19351692 [TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered at two Belgian hospitals. Bogaerts P; Rodriguez-Villalobos H; Bauraing C; Deplano A; Laurent C; Berhin C; Struelens MJ; Glupczynski Y Pathol Biol (Paris); 2010 Feb; 58(1):78-83. PubMed ID: 19892478 [TBL] [Abstract][Full Text] [Related]
5. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590 [TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia. Matsumura Y; Nagao M; Iguchi M; Yagi T; Komori T; Fujita N; Yamamoto M; Matsushima A; Takakura S; Ichiyama S Clin Microbiol Infect; 2013 Feb; 19(2):161-8. PubMed ID: 22332968 [TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Oteo J; Diestra K; Juan C; Bautista V; Novais A; Pérez-Vázquez M; Moyá B; Miró E; Coque TM; Oliver A; Cantón R; Navarro F; Campos J; Int J Antimicrob Agents; 2009 Aug; 34(2):173-6. PubMed ID: 19464856 [TBL] [Abstract][Full Text] [Related]
8. Epidemiology of Escherichia coli clinical isolates producing AmpC plasmidic beta-lactamase during a 5-year period in a French teaching Hospital. Corvec S; Crémet L; Leprince C; Dauvergne S; Reynaud A; Lepelletier D; Caroff N Diagn Microbiol Infect Dis; 2010 Jul; 67(3):277-81. PubMed ID: 20462724 [TBL] [Abstract][Full Text] [Related]
9. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. Leflon-Guibout V; Blanco J; Amaqdouf K; Mora A; Guize L; Nicolas-Chanoine MH J Clin Microbiol; 2008 Dec; 46(12):3900-5. PubMed ID: 18842941 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. Jørgensen RL; Nielsen JB; Friis-Møller A; Fjeldsøe-Nielsen H; Schønning K J Antimicrob Chemother; 2010 Mar; 65(3):460-4. PubMed ID: 20097787 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan. Matsumura Y; Yamamoto M; Higuchi T; Komori T; Tsuboi F; Hayashi A; Sugimoto Y; Hotta G; Matsushima A; Nagao M; Takakura S; Ichiyama S Int J Antimicrob Agents; 2012 Aug; 40(2):158-62. PubMed ID: 22743014 [TBL] [Abstract][Full Text] [Related]
12. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. Yumuk Z; Afacan G; Nicolas-Chanoine MH; Sotto A; Lavigne JP J Antimicrob Chemother; 2008 Aug; 62(2):284-8. PubMed ID: 18453527 [TBL] [Abstract][Full Text] [Related]
13. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. Haldorsen B; Aasnaes B; Dahl KH; Hanssen AM; Simonsen GS; Walsh TR; Sundsfjord A; Lundblad EW J Antimicrob Chemother; 2008 Oct; 62(4):694-702. PubMed ID: 18583329 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Simner PJ; Zhanel GG; Pitout J; Tailor F; McCracken M; Mulvey MR; Lagacé-Wiens PR; Adam HJ; Hoban DJ; Diagn Microbiol Infect Dis; 2011 Mar; 69(3):326-34. PubMed ID: 21353961 [TBL] [Abstract][Full Text] [Related]
15. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Peirano G; Costello M; Pitout JD Int J Antimicrob Agents; 2010 Jul; 36(1):19-23. PubMed ID: 20359869 [TBL] [Abstract][Full Text] [Related]
16. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-β-lactamase-producing Escherichia coli in Japan. Matsumura Y; Yamamoto M; Nagao M; Hotta G; Matsushima A; Ito Y; Takakura S; Ichiyama S; J Antimicrob Chemother; 2012 Nov; 67(11):2612-20. PubMed ID: 22843833 [TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. Mammeri H; Eb F; Berkani A; Nordmann P J Antimicrob Chemother; 2008 Mar; 61(3):498-503. PubMed ID: 18250231 [TBL] [Abstract][Full Text] [Related]
18. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing Escherichia coli among companion animals. Ewers C; Grobbel M; Stamm I; Kopp PA; Diehl I; Semmler T; Fruth A; Beutlich J; Guerra B; Wieler LH; Guenther S J Antimicrob Chemother; 2010 Apr; 65(4):651-60. PubMed ID: 20118165 [TBL] [Abstract][Full Text] [Related]
19. Characterization of third-generation cephalosporin-resistant Escherichia coli from bloodstream infections in Denmark. Hansen F; Olsen SS; Heltberg O; Justesen US; Fuglsang-Damgaard D; Knudsen JD; Hammerum AM Microb Drug Resist; 2014 Aug; 20(4):316-24. PubMed ID: 24517383 [TBL] [Abstract][Full Text] [Related]
20. Emergence of clonal groups O1:HNM-D-ST59, O15:H1-D-ST393, O20:H34/HNM-D-ST354, O25b:H4-B2-ST131 and ONT:H21,42-B1-ST101 among CTX-M-14-producing Escherichia coli clinical isolates in Galicia, northwest Spain. Mora A; Blanco M; López C; Mamani R; Blanco JE; Alonso MP; García-Garrote F; Dahbi G; Herrera A; Fernández A; Fernández B; Agulla A; Bou G; Blanco J Int J Antimicrob Agents; 2011 Jan; 37(1):16-21. PubMed ID: 21075606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]